Abstract: A process for process for preparing 6-isopropenyl-3-methyl-9-decenyl acetate of the following formula (3), wherein Ac represents an acetyl group, the process comprising steps of: preparing a nucleophilic reagent, 5-isopropenyl-2-methyl-8-nonenyl compound, of the following general formula (1): wherein M1 represents Li, MgZ1, ZnZ1, Cu, CuZ1, or CuLiZ1, wherein Z1 represents a halogen atom or a 5-isopropenyl-2-methyl-8-nonenyl group, from a 5-isopropenyl-2-methyl-8-nonenyl halide compound of the following general formula (4): wherein X1 represents a halogen atom; subjecting the nucleophilic reagent (1), 5-isopropenyl-2-methyl-8-nonenyl compound, to an addition reaction with at least one electrophilic reagent selected from the group consisting of formaldehyde, paraformaldehyde, and 1,3,5-trioxane, followed by a hydrolysis reaction to form 6-isopropenyl-3-methyl-9-decenol of the following formula (2); and acetylating 6-isopropenyl-3-methyl-9-decenol (2) to form 6-isopropenyl-3-methyl-9-decenyl acetate (3).

Abstract: Provided is a 3-acyloxymethyl-3-butenal acetal compound of General Formula (10): wherein R1 and R2, which may be the same or different, are each an alkyl group having 1 to 6 carbon atoms, or are bonded to each other to form a divalent alkylene group having 2 to 12 carbon atoms, and X1 is an acyloxy group having 1 to 6 carbon atoms.

Abstract: The present invention relates to a method for preventing transmission of influenza, wherein said method comprises administering an effective amount of a compound to a patient having an influenza virus infection, herein referred to as “index patient”, wherein the compound has one of the formulae (I) and (II), or its pharmaceutically acceptable salt. The compound to be used in the present invention reduces infectivity of the influenza virus of the index patient, and therefore, reduces the risk of the index patient to trigger an influenza epidemic or an influenza pandemic as compared to a control patient.

Abstract: An objective of the present invention is to provide methods for promoting antigen uptake into cells by antigen-binding molecules, methods for increasing the number of times of antigen binding by one antigen-binding molecule, methods for promoting reduction of the antigen concentration in plasma by administering antigen-binding molecules, and methods for improving the plasma retention of an antigen-binding molecule, as well as antigen-binding molecules that allow enhanced antigen uptake into cells, antigen-binding molecules having an increased number of times of antigen binding, antigen-binding molecules that can promote reduction of the antigen concentration in plasma when administered, antigen-binding molecules with improved plasma retention, pharmaceutical compositions comprising the above antigen-binding molecules, and methods for producing them. The present inventors revealed that the above objective can be achieved by using antigen-binding molecules that show calcium-dependent antigen-antibody reaction.

Abstract: The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human FcRn under an acidic pH range condition; (ii) of binding under a neutral pH range condition to human Fc receptor stronger than native human IgG, and (iii) that its antigen-binding activity alters according to the ion concentration.

Abstract: An optical circuit element formed on a substrate, the optical circuit element includes a first waveguide and a second waveguide, the second waveguide having a shape in a width direction, the shape being asymmetrical to the first waveguide. The first waveguide includes a first segment and a second segment, the first segment having a width that changes along a light propagation direction, the second segment continuous with the first segment. The second waveguide includes a coupled waveguide adjacent to the second segment of the first waveguide. At least one of the second segment and the coupled waveguide has a shape with a width that changes along the light propagation direction.

Abstract: A method for manufacturing a light-emitting element includes: providing a structure body including: a semiconductor structure body having a first surface, a second surface located on a side opposite to the first surface, and a lateral surface that connects the first surface and the second surface, a first insulating film covering the lateral surface of the semiconductor structure body, a second insulation film covering the first surface of the semiconductor structure body and an upper surface of the first insulating film on a first surface side, and a substrate facing the second surface of the semiconductor structure body; forming a mask on a part of the second insulating film located above the first surface of the semiconductor structure body; and removing a part of the second insulating film located around the mask in a top view and exposed from the mask.

Abstract: A braking control system includes obstacle detection means for detecting an obstacle ahead of a vehicle, first collision determination means for determining whether the vehicle would collide with the obstacle ahead of the vehicle, following vehicle detection means for detecting a following vehicle traveling behind the vehicle, information acquisition means for acquiring a maximum deceleration set in the following vehicle, second collision determination means for determining whether the following vehicle would collide with the vehicle based on the maximum deceleration, and braking control means for controlling braking means of the vehicle so that an absolute value of a deceleration of the vehicle does not exceed an absolute value of the maximum deceleration of the following vehicle when the first collision determination means determines that the vehicle would collide with the obstacle and the second collision determination means determines that the following vehicle would collide with the vehicle.

Abstract: Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.

Abstract: A driving support system includes: an information acquisition unit configured to acquire traveling characteristic information on a vehicle; a storage unit in which a dynamic map is stored, the dynamic map being a map in which static base map information, dynamic environmental information, and the traveling characteristic information acquired by the information acquisition unit are associated with each other; a collision determination unit configured to determine whether or not there is a possibility that the vehicle has a collision, based on the dynamic map stored in the storage unit; and a control unit configured to, in a case where the collision determination unit determines that there is a possibility that the vehicle has a collision, control the vehicle such that the vehicle avoids the collision.

Abstract: A biochip is capable of highly sensitively detecting a measurement target substance. The biochip includes a selective-binding substance capable of selectively binding to the measurement target substance, the selective-binding substance being immobilized on a surface of a substrate through a polymer containing a unit represented by Formula (Ia) or (Ib): wherein, R1 represents C1-C4 alkylene; R2 represents R3, OR4, or NHR5; R3 and R5 each independently represent a hydrogen atom or C1-C4 alkyl; R4 represents C1-C4 alkyl; R6 represents C1-C2 alkylene; and R7 and R8 each independently represent a hydrogen atom or C1-C4 alkyl.

Abstract: The present disclosure provides antibodies capable of distinguishing between wild-type FGFR3 and FGFR3 S249C mutants. Using these antibodies, antigen-binding molecules capable of selectively damaging tumor cells expressing an FGFR3 S249C mutant were constructed.

Abstract: A mode converter for converting mode of propagating light is provided. The mode converter includes: a mode order conversion unit that includes an input-side first rib unit, an output-side first rib unit that extends along the input-side first rib unit, and a first slab unit arranged between the input-side first rib unit and the output-side first rib unit; and a rib channel conversion unit that includes an output-side second rib unit that is in contact with the output-side first rib unit, a second slab unit that is in contact with the first slab unit and a side surface of the output-side second rib unit, and a third slab unit that is in contact with another side surface of the output-side second rib unit.

Abstract: In an aspect, the present invention provides a structure, a structure-manufacturing method, a cell-sorting method, or the like. In an aspect, a structure (1) of the present invention is a structure including a first substrate (10) and a second substrate (20) disposed to face one side of the first substrate (10), in which the first substrate (10) has a plurality of depressions (11) which are open to the other side of the first substrate and each of which has a size that enables each of the depressions to capture one unit of a cell, at least some of the depressions (11) have communication holes (12) which communicate with one side and the other side of the first substrate and each of which has a size that enables secretions secreted from the cell to move through the communication holes, the second substrate (20) can include accumulation portions (13) in which the secretions moving through the communication holes (12) are accumulated, and the accumulation portions (13) can correspond to the depressions (11).

Abstract: Provided is a method for producing a compound represented by formula (III) from a compound represented by formula (I) as a starting material.

Abstract: A braking control system includes obstacle detection means for detecting an obstacle ahead of a vehicle, first collision determination means for determining whether the vehicle would collide with the obstacle ahead of the vehicle, following vehicle detection means for detecting a following vehicle traveling behind the vehicle, information acquisition means for acquiring a maximum deceleration set in the following vehicle, second collision determination means for determining whether the following vehicle would collide with the vehicle based on the maximum deceleration, and braking control means for controlling braking means of the vehicle so that an absolute value of a deceleration of the vehicle does not exceed an absolute value of the maximum deceleration of the following vehicle when the first collision determination means determines that the vehicle would collide with the obstacle and the second collision determination means determines that the following vehicle would collide with the vehicle.

Abstract: A mode converter for converting mode of propagating light is provided. The mode converter includes: a mode order conversion unit that includes an input-side first rib unit, an output-side first rib unit that extends along the input-side first rib unit, and a first slab unit arranged between the input-side first rib unit and the output-side first rib unit; and a rib channel conversion unit that includes an output-side second rib unit that is in contact with the output-side first rib unit, a second slab unit that is in contact with the first slab unit and a side surface of the output-side second rib unit, and a third slab unit that is in contact with another side surface of the output-side second rib unit.

Abstract: An optical circuit element formed on a substrate, the optical circuit element includes a first waveguide and a second waveguide, the second waveguide having a shape in a width direction, the shape being asymmetrical to the first waveguide. The first waveguide includes a first segment and a second segment, the first segment having a width that changes along a light propagation direction, the second segment continuous with the first segment. The second waveguide includes a coupled waveguide adjacent to the second segment of the first waveguide. At least one of the second segment and the coupled waveguide has a shape with a width that changes along the light propagation direction.

Abstract: An objective of the invention is to provide an antibody, a composition for use in detecting or capturing a polypeptide in a sample, and a method for detecting or capturing a polypeptide in sample. The disclosure provides an antibody, a composition for use in detecting or capturing a polypeptide in a sample, and a method for detecting or capturing a polypeptide in sample.

Abstract: Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.